These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 30553007)
1. Revival of a potent therapeutic maytansinoid agent using a strategy that combines covalent drug conjugation with sequential nanoparticle assembly. Xie K; Song S; Zhou L; Wan J; Qiao Y; Wang M; Xie H; Zhou L; Zheng S; Wang H Int J Pharm; 2019 Feb; 556():159-171. PubMed ID: 30553007 [TBL] [Abstract][Full Text] [Related]
2. Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity. Wang H; Wu J; Xu L; Xie K; Chen C; Dong Y Chem Commun (Camb); 2017 Feb; 53(17):2618-2621. PubMed ID: 28195282 [TBL] [Abstract][Full Text] [Related]
3. Nanoparticles Encapsulating Nitrosylated Maytansine To Enhance Radiation Therapy. Gao S; Zhang W; Wang R; Hopkins SP; Spagnoli JC; Racin M; Bai L; Li L; Jiang W; Yang X; Lee C; Nagata K; Howerth EW; Handa H; Xie J; Ma Q; Kumar A ACS Nano; 2020 Feb; 14(2):1468-1481. PubMed ID: 31939662 [TBL] [Abstract][Full Text] [Related]
4. EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer. Li Y; Duo Y; Bao S; He L; Ling K; Luo J; Zhang Y; Huang H; Zhang H; Yu X Int J Nanomedicine; 2017; 12():6239-6257. PubMed ID: 28894364 [TBL] [Abstract][Full Text] [Related]
5. DM1 Loaded Ultrasmall Gold Nanoparticles Display Significant Efficacy and Improved Tolerability in Murine Models of Hepatocellular Carcinoma. Hale SJM; Perrins RD; Garcı A CE; Pace A; Peral U; Patel KR; Robinson A; Williams P; Ding Y; Saito G; Rodriguez MÁ; Perera I; Barrientos A; Conlon K; Damment S; Porter J; Coulter T Bioconjug Chem; 2019 Mar; 30(3):703-713. PubMed ID: 30582799 [TBL] [Abstract][Full Text] [Related]
6. Enhancing the anti-colon cancer activity of quercetin by self-assembled micelles. Xu G; Shi H; Ren L; Gou H; Gong D; Gao X; Huang N Int J Nanomedicine; 2015; 10():2051-63. PubMed ID: 25844036 [TBL] [Abstract][Full Text] [Related]
7. Self-assembling poly(ethylene glycol)-block-polylactide-cabazitaxel conjugate nanoparticles for anticancer therapy with high efficacy and low in vivo toxicity. Shuai Q; Zhao G; Lian X; Wan J; Cen B; Zhang W; Liu J; Su W; Wang H Int J Pharm; 2020 Jan; 574():118879. PubMed ID: 31770581 [TBL] [Abstract][Full Text] [Related]
8. A highly potent maytansinoid analogue and its use as a cytotoxic therapeutic agent in gold nanoparticles for the treatment of hepatocellular carcinoma. Porter J; Ding Y; Hale SJM; Perrins RD; Robinson A; Mazanetz MP; Wu Y; Ma Y; Conlon K; Coulter T Bioorg Med Chem Lett; 2020 Dec; 30(24):127634. PubMed ID: 33148516 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive study of the drug delivery properties of poly(l-lactide)-poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice. Shalgunov V; Zaytseva-Zotova D; Zintchenko A; Levada T; Shilov Y; Andreyev D; Dzhumashev D; Metelkin E; Urusova A; Demin O; McDonnell K; Troiano G; Zale S; Safarovа E J Control Release; 2017 Sep; 261():31-42. PubMed ID: 28611009 [TBL] [Abstract][Full Text] [Related]
10. Transforming a highly toxic agent DM1 into injectable safe nanomedicines Huang J; Song S; Wang M; Wang H Nanoscale; 2023 Jun; 15(23):10110-10124. PubMed ID: 37255385 [TBL] [Abstract][Full Text] [Related]
11. A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy. Meng H; Zou Y; Zhong P; Meng F; Zhang J; Cheng R; Zhong Z Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28464449 [TBL] [Abstract][Full Text] [Related]
12. A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid. Liang Y; Li S; Wang X; He B; He B; Dai W; Zhang H; Wang X; Wang Y; Zhou D; Zhang Q Theranostics; 2017; 7(13):3306-3318. PubMed ID: 28900511 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907 [TBL] [Abstract][Full Text] [Related]
14. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688 [TBL] [Abstract][Full Text] [Related]
15. Zein nanoparticles as nontoxic delivery system for maytansine in the treatment of non-small cell lung cancer. Yu X; Wu H; Hu H; Dong Z; Dang Y; Qi Q; Wang Y; Du S; Lu Y Drug Deliv; 2020 Dec; 27(1):100-109. PubMed ID: 31870183 [No Abstract] [Full Text] [Related]
16. Technology evaluation: C242-DM1, ImmunoGen Inc. Smith S Curr Opin Mol Ther; 2001 Apr; 3(2):198-203. PubMed ID: 11338934 [TBL] [Abstract][Full Text] [Related]
17. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo. Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391 [TBL] [Abstract][Full Text] [Related]
18. Endoplasmic reticulum-targeted glutathione and pH dual responsive vitamin lipid nanovesicles for tocopheryl DM1 delivery and cancer therapy. Wang YQ; Ji MY; Wang C Int J Pharm; 2020 May; 582():119331. PubMed ID: 32289484 [TBL] [Abstract][Full Text] [Related]
19. Barbaloin loaded polydopamine-polylactide-TPGS (PLA-TPGS) nanoparticles against gastric cancer as a targeted drug delivery system: Studies in vitro and in vivo. Wang YR; Yang SY; Chen GX; Wei P Biochem Biophys Res Commun; 2018 Apr; 499(1):8-16. PubMed ID: 29534962 [TBL] [Abstract][Full Text] [Related]
20. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]